Pirus Ghadjar

List of Publications by Year
in descending order

159 papers	4,172 citations	109321 35 h-index	144013 57 g-index
163 all docs	163 docs citations	163 times ranked	5946 citing authors

#	Article	IF	Citations
1	Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment. Cancers, 2022, 14, 625.	3.7	16
2	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.8	5
3	Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 260-260.	1.6	0
4	Experimental and computational evaluation of capacitive hyperthermia. International Journal of Hyperthermia, 2022, 39, 504-516.	2.5	2
5	Randomized Pilot Trial Using External Yarrow Liver Compress Applications With Metastatic Cancer Patients Suffering From Fatigue: Evaluation of Sympathetic Modulation by Heart Rate Variability Analysis. Integrative Cancer Therapies, 2022, 21, 153473542210812.	2.0	2
6	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). International Journal of Radiation Oncology Biology Physics, 2022, 113, 1025-1035.	0.8	12
7	Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation. Cancers, 2022, 14, 2418.	3.7	2
8	Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. Acta Radiologica, 2021, 62, 1200-1207.	1.1	6
9	Ultrahypofractionation of localized prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 89-96.	2.0	22
10	Mode of Action and Experimental and Clinical Data of Regional Hyperthermia. , 2021, , 141-149.		0
11	Hyperthermie in Kombination mit Radiotherapie in der Tumorbehandlung. Springer Reference Medizin, 2021, , 1-10.	0.0	0
12	Improved patient-specific hyperthermia planning based on parametrized electromagnetic and thermal models for the SIGMA-30 applicator. International Journal of Hyperthermia, 2021, 38, 663-678.	2.5	2
13	Non-thermal membrane effects of electromagnetic fields and therapeutic applications in oncology. International Journal of Hyperthermia, 2021, 38, 715-731.	2.5	20
14	Radiotherapeutic treatment options for oligotopic malignant liver lesions. Radiation Oncology, 2021, 16, 51.	2.7	5
15	Salvage-Radiation Therapy and Regional Hyperthermia for Biochemically Recurrent Prostate Cancer after Radical Prostatectomy (Results of the Planned Interim Analysis). Cancers, 2021, 13, 1133.	3.7	6
16	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology, 2021, 156, 281-293.	0.6	157
17	Patient-Specific Planning for Thermal Magnetic Resonance of Glioblastoma Multiforme. Cancers, 2021, 13, 1867.	3.7	7
18	External application of liver compresses to reduce fatigue in patients with metastatic cancer undergoing radiation therapy, a randomized clinical trial. Radiation Oncology, 2021, 16, 76.	2.7	6

#	Article	IF	Citations
19	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	2.0	11
20	Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study. Oral Oncology, 2021, 116, 105240.	1.5	7
21	Postoperative radiotherapy in prostate cancer. Lancet, The, 2021, 397, 1623.	13.7	3
22	Re: Timing of Radiotherapy After Radical Prostatectomy (RadicalS-RT): A Randomised, Controlled Phase 3 Trial. European Urology, 2021, 80, 117.	1.9	1
23	Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. Radiotherapy and Oncology, 2021, 160, 140-147.	0.6	7
24	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. Strahlentherapie Und Onkologie, 2021, 197, 993-1000.	2.0	3
25	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. European Urology, 2021, 80, 306-315.	1.9	64
26	Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy. Strahlentherapie Und Onkologie, 2020, 196, 229-242.	2.0	6
27	Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732â€“9. European Urology, 2020, 77, e60-e61.	1.9	1
28	Androgen deprivation therapy plus salvage radiotherapy after prostatectomy. Lancet Oncology, The, 2020, 21, e11.	10.7	2
29	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 109-116.	2.0	14
30	Non-thermal effects of radiofrequency electromagnetic fields. Scientific Reports, 2020, 10, 13488.	3.3	46
31	In Regard to Qi etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 107, 224-225.	0.8	0
32	In Regard to Wang etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 107, 855.	0.8	1
33	The Relevance of Complementary and Integrative Medicine in the COVID-19 Pandemic: A Qualitative Review of the Literature. Frontiers in Medicine, 2020, 7, 587749.	2.6	36
34	Radiofrequency applicator concepts for thermal magnetic resonance of brain tumors at 297â€‰MHz (7.0ÂTesla). International Journal of Hyperthermia, 2020, 37, 549-563.	2.5	17
35	Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer. Journal of Clinical Oncology, 2020, 38, 1746-1746.	1.6	1
36	Locoregional peritoneal hyperthermia to enhance the effectiveness of chemotherapy in patients with peritoneal carcinomatosis: a simulation study comparing different locoregional heating systems. International Journal of Hyperthermia, 2020, 37, 76-88.	2.5	14

#	Article	IF	Citations
37	Combined tumor plus nontumor interim FDGâ€PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. International Journal of Cancer, 2020, 147, 1427-1436.	5.1	6
38	PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study. F1000Research, 2020, 9, 1350.	1.6	3
39	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 589-597.	2.0	10
40	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 5-13.	0.6	62
41	Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma. Radiation Oncology, 2019, 14, 160.	2.7	30
42	Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancerâ€"a meta-analysis. Strahlentherapie Und Onkologie, 2019, 195, 1041-1049.	2.0	16
43	Re: Abdenour Nabid, Nathalie Carrier, AndrÃ©-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432â€"31. European Urology, 2019, 75, e61-e62.	1.9	3
44	Physical analysis of temperature-dependent effects of amplitude-modulated electromagnetic hyperthermia. International Journal of Hyperthermia, 2019, 36, 1245-1253.	2.5	23
45	The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer. Deutsches Ärzteblatt International, 2019, 116, 849-856.	0.9	6
46	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma. JAMA Oncology, 2018, 4, 483.	7.1	227
47	Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1752-1761.	6.4	8
48	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 619-626.	2.0	26
49	A novel voxel based homogeneity index: Rationale and clinical implications for whole-brain radiation therapy. Radiotherapy and Oncology, 2018, 128, 229-235.	0.6	2
50	Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control. Radiation Oncology, 2018, 13, 64.	2.7	9
51	Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156â€"65. European Urology, 2018, 73, e63.	1.9	0
52	Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910â€"7. European Urology, 2018, 73, e34-e35.	1.9	1
53	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiotherapy and Oncology, 2018, 126, 257-262.	0.6	19
54	Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma. Radiation Oncology, 2018, 13, 251.	2.7	13

#	Article	IF	Citations
55	Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison. International Journal of Hyperthermia, 2018, 35, 314-322.	2.5	5
56	Optimizing radiotherapy for intermediate-risk localized disease. Nature Reviews Urology, 2018, 15, 470-471.	3.8	2
57	Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No.â€‰015/082, November 2017) â€“ Recommendations and Statements for Girls and Women. Geburtshilfe Und Frauenheilkunde, 2018, 78, 567-584.	1.8	56
58	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	2.7	34
59	Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database. Radiation Oncology, 2018, 13, 113.	2.7	6
60	Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era?. Radiation Oncology, 2018, 13, 3.	2.7	9
61	Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements. International Journal of Hyperthermia, 2017, 33, 471-482.	2.5	86
62	Planning study for Merkel cell carcinoma based on the relapse pattern. Radiotherapy and Oncology, 2017, 123, 154-157.	0.6	2
63	In Regard to Pisansky etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 438-439.	0.8	1
64	Spinal cord constraints in the era of high-precision radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 561-569.	2.0	5
65	Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer. European Urology, 2017, 72, 319.	1.9	0
66	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the <scp>SAKK</scp> 09/10 randomized trial on prostate cancer. BJU International, 2017, 120, E45-E51.	2.5	13
67	Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy. Strahlentherapie Und Onkologie, 2017, 193, 700-706.	2.0	25
68	Current status and perspectives of interventional clinical trials for glioblastoma â€“ analysis of ClinicalTrials.gov. Radiation Oncology, 2017, 12, 1.	2.7	87
69	Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. Radiation Oncology, 2017, 12, 125.	2.7	7
70	Radiofrequency applicator concepts for simultaneous MR imaging and hyperthermia treatment of glioblastoma multiforme. Current Directions in Biomedical Engineering, 2017, 3, 473-477.	0.4	13
71	Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS ONE, 2017, 12, e0186341.	2.5	15
72	Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiation Oncology, 2017, 12, 140.	2.7	34

#	Article	IF	Citations
73	Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?. Journal of Clinical Oncology, 2017, 35, 1490-1491.	1.6	1
74	Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy. Frontiers in Oncology, 2016, 6, 48.	2.8	3
75	Reply to C. Cozzarini et al. Journal of Clinical Oncology, 2016, 34, 1705-1706.	1.6	0
76	Accelerated hyperfractionation plus temozolomide in glioblastoma. Radiation Oncology, 2016, 11, 70.	2.7	9
77	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21â€“30. European Urology, 2016, 70, e11-e12.	1.9	5
78	Radiotherapy for Non-Hodgkinâ€™s lymphoma: still standard practice and not an outdated treatment option. Radiation Oncology, 2016, 11, 110.	2.7	28
79	Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study. Rare Tumors, 2016, 8, 118-123.	0.6	31
80	Biological modelling of the radiation dose escalation effect of regional hyperthermia in cervical cancer. Radiation Oncology, 2016, 11, 14.	2.7	37
81	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. Strahlentherapie Und Onkologie, 2016, 192, 552-560.	2.0	13
82	Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapyâ€“Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. European Urology Focus, 2016, 2, 514-521.	3.1	11
83	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. Radiation Oncology, 2016, 11, 48.	2.7	12
84	Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives. Radiation Oncology, 2016, 11, 65.	2.7	25
85	Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Into Imaging, 2016, 7, 205-214.	3.4	45
86	Unilateral and bilateral neck SIB for head and neck cancer patients. Strahlentherapie Und Onkologie, 2016, 192, 232-239.	2.0	21
87	Magnetic resonance thermometry: Methodology, pitfalls and practical solutions. International Journal of Hyperthermia, 2016, 32, 63-75.	2.5	173
88	Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients. Strahlentherapie Und Onkologie, 2016, 192, 17-24.	2.0	14
89	Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. World Journal of Gastroenterology, 2016, 22, 833.	3.3	58
90	Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial. Radiation Oncology, 2015, 10, 138.	2.7	8

#	Article	IF	Citations
91	Regional hyperthermia of the abdomen, a pilot study towards the treatment of peritoneal carcinomatosis. Radiation Oncology, 2015, 10, 157.	2.7	12
92	Thermal magnetic resonance: physics considerations and electromagnetic field simulations up to 23.5 Tesla (1GHz). Radiation Oncology, 2015, 10, 201.	2.7	39
93	Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. Radiation Oncology, 2015, 10, 244.	2.7	14
94	The oncologic role of local treatment in primary metastatic prostate cancer. World Journal of Urology, 2015, 33, 755-761.	2.2	14
95	Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6ÂGy With Concurrent 5-FU/Mitomycin C Is Superior to HART of 77.6ÂGy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95-06 Randomized Phase III Trial. International Journal of Radiation Oncology Biology Physics, 2015, 91, 916-924.	0.8	37
96	Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. Radiation Oncology, 2015, 10, 50.	2.7	40
97	Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 904-910.	0.8	52
98	What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 164.e1-164.e9.	1.6	35
99	Regional nodal relapse in surgically staged Merkel cell carcinoma. Strahlentherapie Und Onkologie, 2015, 191, 51-58.	2.0	17
100	Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer. Current Urology Reports, 2015, 16, 28.	2.2	1
101	Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiation Oncology, 2015, 10, 21.	2.7	58
102	Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. Radiation Oncology, 2015, 10, 20.	2.7	8
103	Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. International Journal of Hyperthermia, 2015, 31, 609-614.	2.5	173
104	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. Journal of Clinical Oncology, 2015, 33, 4158-4166.	1.6	99
105	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. European Urology Focus, 2015, 1, 173-184.	3.1	11
106	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 265.e1-265.e7.	1.6	14
107	Preferences in the management of highâ€risk prostate cancer among urologists in <scp>E</scp>urope: results of a webâ€based survey. BJU International, 2015, 115, 571-579.	2.5	29
108	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. Journal of Clinical Oncology, 2015, 33, 5038-5038.	1.6	2

#	Article	IF	Citations
109	Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling. Archivos Espanoles De Urologia, 2015, 68, 296-306.	0.2	5
110	RE: Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer. Journal of the National Cancer Institute, 2014, 106, djt464-djt464.	6.3	0
111	Chemokine receptor CCR6 expression is regulated by miR-518a-5p in colorectal cancer cells. Journal of Translational Medicine, 2014, 12, 48.	4.4	19
112	Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial. Radiation Oncology, 2014, 9, 24.	2.7	17
113	Reducing radiation dose in the diagnosis of pulmonary embolism using adaptive statistical iterative reconstruction and lower tube potential in computed tomography. European Radiology, 2014, 24, 2685-2691.	4.5	24
114	Comparison of highâ€dose (86.4â€‰<scp>G</scp>y) <scp>IMRT</scp> vs combined brachytherapy plus <scp>IMRT</scp> for intermediateâ€risk prostate cancer. BJU International, 2014, 114, 360-367.	2.5	125
115	Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiation Oncology, 2014, 9, 122.	2.7	28
116	Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 339-344.	0.8	122
117	Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94). Oral Oncology, 2013, 49, 1006-1009.	1.5	1
118	Prognostic Importance of Gleason 7 Disease Among Patients Treated With External Beam Radiation Therapy for Prostate Cancer: Results of a Detailed Biopsy Core Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1254-1261.	0.8	20
119	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. International Journal of Radiation Oncology Biology Physics, 2013, 87, 534-541.	0.8	23
120	Diagnosis and treatment outcomes for patients with lymphoma of the parotid gland. Laryngoscope, 2013, 123, 662-669.	2.0	15
121	Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, 313-320.	0.4	37
122	Patterns and Predictors of Amelioration of Genitourinary Toxicity After High-dose Intensity-modulated Radiation Therapy for Localized Prostate Cancer: Implications for Defining Postradiotherapy Urinary Toxicity. European Urology, 2013, 64, 931-938.	1.9	38
123	miR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: Significance of their regulation. Oncology Reports, 2013, 30, 1285-1292.	2.6	34
124	Chemotherapy with irradiation in salivary gland carcinomas (SGC): A Rare Cancer Network study (RCN).. Journal of Clinical Oncology, 2013, 31, e17019-e17019.	1.6	0
125	Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions. Prostate Cancer, 2012, 2012, 1-8.	0.6	6
126	Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of a Randomized Phase III Trial (SAKK 10/94). International Journal of Radiation Oncology Biology Physics, 2012, 82, 524-531.	0.8	34

#	Article	IF	Citations
127	Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study. International Journal of Radiation Oncology Biology Physics, 2012, 83, 284-291.	0.8	53
128	High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1205-1212.	0.8	41
129	Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiotherapy and Oncology, 2012, 104, 213-218.	0.6	26
130	miR-21 functionally interacts with the 3â€²UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells. Cancer Letters, 2012, 316, 105-112.	7.2	35
131	Comparative analysis of prostateâ€specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 2012, 110, E431-2; author reply E432.	2.5	8
132	Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. Radiation Oncology, 2012, 7, 175.	2.7	29
133	Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy. Radiation Oncology, 2012, 7, 132.	2.7	45
134	Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. Eur Urol 2012;61:443â€“51. European Urology, 2012, 61, e39.	1.9	4
135	The Essential Role of Radiotherapy in the Treatment of Merkel Cell Carcinoma: A Study From the Rare Cancer Network. International Journal of Radiation Oncology Biology Physics, 2011, 81, e583-e591.	0.8	67
136	Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU International, 2011, 107, 894-897.	2.5	23
137	Letter to the Editor on: A. Siegmann et al. Dose Escalation for Patients with Decreasing PSA during Radiotherapy for Elevated PSA after Radical Prostatectomy Improves Biochemical ProgressionFree Survival. Results of a Retrospective Study. Strahlentherapie Und Onkologie, 2011, 187, 763-764.	2.0	1
138	Urethral toxicity vs. cancer controlâ€”Lessons to be learned from highâ€“dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Brachytherapy, 2011, 10, 286-294.	0.5	13
139	Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies. Tumor Biology, 2011, 32, 189-196.	1.8	21
140	CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells. Journal of Translational Medicine, 2011, 9, 22.	4.4	30
141	Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 2011, 117, 3532-3532.	4.1	2
142	In Response to Dr. Lacout etÂal.. International Journal of Radiation Oncology Biology Physics, 2011, 80, 962.	0.8	0
143	Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases. World Journal of Gastroenterology, 2011, 17, 3109-16.	3.3	13
144	High-Dose (80 Gy) Intensity-Modulated Radiation Therapy with Daily Image-Guidance as Primary treatment for Localized Prostate Cancer. Strahlentherapie Und Onkologie, 2010, 186, 687-692.	2.0	21

#	Article	IF	Citations
145	Quantitative Analysis of Extracapsular Extension of Metastatic Lymph Nodes and its Significance in Radiotherapy Planning in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1127-1132.	0.8	48
146	Incidence of Small Lymph Node Metastases With Evidence of Extracapsular Extension: Clinical Implications in Patients With Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1366-1372.	0.8	24
147	Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. Radiation Oncology, 2010, 5, 3.	2.7	9
148	CCL20/CCR6 expression profile in pancreatic cancer. Journal of Translational Medicine, 2010, 8, 45.	4.4	53
149	The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. International Journal of Cancer, 2009, 125, 741-745.	5.1	127
150	Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy, 2009, 8, 45-51.	0.5	72
151	MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clinical and Experimental Metastasis, 2009, 26, 809-815.	3.3	36
152	Use of Gold Markers for Setup in Image-Guided Fractionated High-Dose-Rate Brachytherapy as a Monotherapy for Prostate Cancer. Strahlentherapie Und Onkologie, 2009, 185, 731-735.	2.0	12
153	Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiotherapy and Oncology, 2009, 91, 237-242.	0.6	22
154	Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1181-1189.	2.5	44
155	Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Radiation Oncology, 2008, 3, 22.	2.7	3
156	Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiation Oncology, 2008, 3, 35.	2.7	27
157	Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands. International Journal of Cancer, 2008, 123, 1565-1572.	5.1	8
158	Nuclear expression of CXCR4 in tumor cells of nonâ€“small cell lung cancer is correlated with lymph node metastasis. Human Pathology, 2008, 39, 1751-1755.	2.0	63
159	Chemokine Receptor CCR6 Expression Level and Liver Metastases in Colorectal Cancer. Journal of Clinical Oncology, 2006, 24, 1910-1916.	1.6	126